Europe Radiopharmaceuticals Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2024 –2030 |
 Marktgröße (Basisjahr) | |
 Marktgröße (Prognosejahr) | USD 3,487.24 |
 CAGR |
% |
| Wichtige Marktteilnehmer |
>Europäischer Markt für Radiopharmazeutika nach Typ (diagnostische Radiopharmazeutika und therapeutische Radiopharmazeutika), Anwendung (diagnostisch und therapeutisch), Quelle (Kernreaktoren und Zyklotrone), Endverbraucher (Krankenhäuser, Diagnosezentren, Krebsforschungsinstitute, ambulante chirurgische Zentren und andere) – Branchentrends und Prognose bis 2030.
Marktanalyse und Einblicke für Radiopharmaka in Europa
Das zunehmende Bewusstsein für Radiopharmaka in Europa hat die Nachfrage nach diesem Markt erhöht. Die steigenden Gesundheitsausgaben für bessere Gesundheitsdienste tragen ebenfalls zum Wachstum des Marktes bei. Die wichtigsten Marktteilnehmer konzentrieren sich in dieser entscheidenden Phase auf die Einführung und Zulassung verschiedener Dienste. Darüber hinaus trägt auch die zunehmende Weiterentwicklung von Techniken zur Arzneimittelentwicklung zur steigenden Nachfrage nach Radiopharmaka bei.
Der europäische Markt für Radiopharmaka dürfte aufgrund der zunehmenden Zahl von Marktteilnehmern und der Verfügbarkeit fortschrittlicher Dienste wachsen. Darüber hinaus sind die Hersteller in Entwicklungsaktivitäten involviert, um neue Dienste auf den Markt zu bringen. Das zunehmende Wachstum im Bereich der Arzneimittelentwicklung treibt das Marktwachstum weiter an. Allerdings dürften Schwierigkeiten wie das Fehlen standardisierter Protokolle und der Mangel an qualifizierten Fachkräften das Marktwachstum bremsen.
Die steigenden Gesundheitsausgaben für Fortschritt und Arzneimittelentwicklung dürften dem Markt Chancen eröffnen. Der zunehmende Einsatz alternativer Behandlungen könnte das Marktwachstum jedoch bremsen.
Laut einer Analyse von Data Bridge Market Research dürfte der europäische Markt für Radiopharmaka bis 2030 einen Wert von 3.487,24 Millionen US-Dollar erreichen, was einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 5,9 % während des Prognosezeitraums 2023–2030 entspricht.
|
Berichtsmetrik |
Details |
|
Prognosezeitraum |
2023 bis 2030 |
|
Basisjahr |
2022 |
|
Historisches Jahr |
2021 (Anpassbar auf 2015 – 2020) |
|
Quantitative Einheiten |
Umsatz in Mio. USD |
|
Abgedeckte Segmente |
Typ (diagnostische Radiopharmaka und therapeutische Radiopharmaka), Anwendung (diagnostisch und therapeutisch), Quelle (Kernreaktoren und Zyklotrone), Endbenutzer (Krankenhäuser, Diagnosezentren, Krebsforschungsinstitute, ambulante chirurgische Zentren und andere) |
|
Abgedeckte Länder |
Deutschland, Großbritannien, Frankreich, Italien, Spanien, Belgien, Polen, Russland, Norwegen, Türkei, Österreich, Irland, Ungarn, Niederlande, Schweiz und Rest von Europa |
|
Abgedeckte Marktteilnehmer |
Cardinal Health, Advanced Accelerator Applications, ein Unternehmen von Novartis, Lantheus, CURIUM, Jubilant Radiopharma, ein Unternehmen von Jubilant Pharmova, China Isotope & Radiation Corporation., Siemens Healthcare GmbH, Bracco, Eckert & Ziegler, SHINE Technologies, LLC, IBA Worldwide, Institute of Isotopes und andere. |
Definition des europäischen Radiopharmazeutika-Marktes
Ein Radiopharmakon enthält eine radioaktive Substanz in Verbindung mit einem oder mehreren Inhaltsstoffen, die zur Diagnose, zur Bestimmung des Krankheitsstadiums, zur Überwachung der Behandlung oder zur Bereitstellung einer Therapie dienen. Radiopharmakone umfassen eine Gruppe radioaktiver Wirkstoffe, die entweder für diagnostische oder therapeutische Eingriffe verwendet werden. Dies sind die Arzneimittel, die ein Radionuklid enthalten. Die meisten Radiopharmakone sind eine Kombination aus einem radioaktiven Nuklid oder Radionuklid und einem biologisch aktiven Molekül oder Arzneimittel, das als Träger fungiert und die Lokalisierung und Bioverteilung bestimmt.
Dynamik des europäischen Radiopharmazeutika-Marktes
In diesem Abschnitt geht es um das Verständnis der Markttreiber, Chancen, Einschränkungen und Herausforderungen. All dies wird im Folgenden ausführlich erläutert:
Treiber
- Die wachsende Nachfrage nach Radiopharmaka in der Diagnostik und im klinischen Einsatz
Radiopharmaka sind aus der Organdiagnostik und der Behandlung pathologischer Erkrankungen nicht mehr wegzudenken. Sie werden in der bildgebenden Diagnostik und Strahlentherapie eingesetzt. Diagnostische Radiopharmaka besitzen keine pharmakologischen Effekte und ihre Verabreichung geht auch nicht mit relevanten klinischen Nebenwirkungen einher.
Die Zahl der im klinischen Einsatz befindlichen Radiopharmaka wächst rapide, wodurch die medizinische Gemeinschaft besseren Zugang zu detaillierten Informationen über die Eigenschaften der verschiedenen Tumorarten erhält. Radionuklide gewinnen auch an Bedeutung, da sie bei einer zunehmenden Zahl bösartiger Erkrankungen eine palliative und kurative Behandlung ermöglichen.
Gelegenheit
- Die steigenden Forschungs- und Entwicklungsausgaben für Radiopharmaka
Zu den technologischen Fortschritten gehört die Verbesserung der Stabilität und Wirksamkeit herkömmlicher Arzneimittel. Die Biotechnologie- und Pharmaunternehmen investieren kontinuierlich in Forschung und Entwicklung, um den Kunden innovative Dienstleistungen für Diagnostik und Medikamente anzubieten und ihre Marktpräsenz zu stärken. Radiopharmaka spielen in der klinischen Entwicklung eine dynamische Rolle. Während die Diagnostikbranche aufgrund der Einführung neuer Technologien auf dem Markt einem ständigen Wandel unterliegt, wächst die Pharma- und Biotechnologiebranche aufgrund erhöhter Investitionen in Radiopharmaunternehmen sowie Fusionen und Übernahmen sowie der Einführung innovativer Bildgebungstechnologien zur Unterstützung klinischer Studien für verschiedene Krankheiten weiter.
Die steigenden Forschungs- und Entwicklungsausgaben in Pharma- und Biotechnologieunternehmen stellen eine Chance für das Wachstum des europäischen Radiopharmakamarktes dar.
Einschränkungen /Herausforderungen
- Strenge Vorschriften für Radiopharmaka
Radiopharmaka sind Wirkstoffe, die zur Diagnose bestimmter medizinischer Probleme oder zur Behandlung bestimmter Krankheiten eingesetzt werden. Daher stellen die unterschiedlichen staatlichen Vorschriften für die Markteinführung eines Produkts eine große Einschränkung dar. Jedes Land hat seine eigenen Vorschriften und unterschiedliche Stellen für Regulierungsverfahren. Strenge Regulierungs- und Produktzulassungsrichtlinien dürften die Entwicklung des Radiopharmakamarktes behindern.
Die strengen Vorschriften der Regierungsbehörden sind notwendig, um den Ruf des Unternehmens zu schützen, Unzuverlässigkeit der Produkte zu verhindern und das Vertrauen der Verbraucher zu stärken. Um die Zulassung eines neuen Medikaments durch die zuständige Behörde zu erhalten, sind mehrere Investitions- und Testphasen erforderlich. Diese Phasen bestehen aus verschiedenen Phasen, und jede Phase hat unterschiedliche behördliche Anforderungen.
Die Organisation, die die Studie durchführt, muss die erforderlichen Unterlagen der jeweiligen Aufsichtsbehörde des betreffenden Landes vorlegen und sollte gemäß den Richtlinien und der Rechtsprechung des Landes sicher und legal sein.
Allerdings können die strengen regulatorischen Richtlinien zur Regulierung der Radiopharmaka auf dem Markt das Marktwachstum behindern, und die Rücknahme von Medikamenten vom Markt aufgrund komplexer Regulierungen kann sich negativ auf den Markt auswirken, was voraussichtlich das Marktwachstum bremsen wird.
- Hohe Kosten für Entwicklung und Einführung von Radiopharmaka
Radiopharmaka spielen in Gesundheitseinrichtungen eine wichtige Rolle und sorgen für Sicherheit und Effizienz in Pharma- und Biotechnologieunternehmen. Sie haben hervorragende Eigenschaften, aber gleichzeitig auch einige Nachteile. Aufgrund des technologischen Fortschritts wird für Radiopharmaka ein Wachstum erwartet. Mehrere Hindernisse könnten den Markt jedoch daran hindern, sein volles Potenzial auszuschöpfen, da die Entwicklung und Implementierung von Radiopharmaka teuer ist und der Markt möglicherweise nicht schnell wächst. Höhere Entwicklungs- und Implementierungskosten sowie Anforderungen an geeignete Oberflächen begrenzen daher das Marktwachstum und führen zu zusätzlichen Infrastruktur- und Betriebskosten.
Jüngste Entwicklungen
- Im Oktober 2023 stellte IBA bei jedem Treffen in Barcelona AKURACY vor, eine integrierte Lösung für die Herzbildgebung bei Haustieren. Das Unternehmen ist davon überzeugt und gibt an, dass dies eine einzigartige integrierte Lösung für die Myokardperfusionsbildgebung bei Haustieren ist.
- Im April 2023 gaben Lantheus und POINT Biopharma bekannt, dass die FDA den Fast-Track-Status für ¹⁷⁷Lu-PNT2002 zur Behandlung von metastasiertem kastrationsresistentem Prostatakrebs erteilt. Das Unternehmen gab an, dass sich die Radioligandentherapie schnell zu einer weiteren Säule der Krebsbehandlung entwickelt.
Umfang des europäischen Marktes für Radiopharmaka
Der europäische Markt für Radiopharmaka ist in vier wichtige Segmente unterteilt: Typ, Anwendung, Quelle und Endverbraucher. Das Wachstum zwischen den Segmenten hilft Ihnen bei der Analyse von Wachstumsnischen und Strategien zur Marktbearbeitung und zur Bestimmung Ihrer wichtigsten Anwendungsbereiche und der Unterschiede in Ihren Zielmärkten.
Typ
- Diagnostische Radiopharmaka
- Therapeutische Radiopharmaka
Auf der Grundlage des Typs ist der Markt in diagnostische Radiopharmaka und therapeutische Radiopharmaka segmentiert.
Anwendung
- Diagnostik
- Therapeutisch
Auf der Grundlage der Anwendung wird der Markt in Diagnose und Therapie segmentiert.
Quelle
- Kernreaktoren
- Zyklotrone
Auf Grundlage der Quelle wird der Markt in Kernreaktoren und Zyklotrone segmentiert.
Endbenutzer
- Krankenhäuser
- Diagnostikzentren
- Krebsforschungsinstitute
- Ambulante chirurgische Zentren
- Sonstiges
Auf der Grundlage des Endbenutzers ist der Markt in Krankenhäuser, Diagnosezentren, Krebsforschungsinstitute, ambulante chirurgische Zentren und andere segmentiert.
Regionale Analyse/Einblicke zum europäischen Radiopharmazeutika-Markt
Der europäische Markt für Radiopharmaka ist in vier wichtige Segmente unterteilt: Typ, Anwendung, Quelle und Endbenutzer.
Die in diesem Marktbericht abgedeckten Länder sind Deutschland, Großbritannien, Frankreich, Italien, Spanien, Belgien, Polen, Russland, Norwegen, Türkei, Österreich, Irland, Ungarn, Niederlande, Schweiz und das übrige Europa.
Deutschland wird voraussichtlich den Markt dominieren, da die Investitionen in den Gesundheitssektor zunehmen und das Marktwachstum dadurch angekurbelt wird. Deutschland wird voraussichtlich die Region Europa dominieren, da der technologische Fortschritt bei Gesundheits- und Behandlungsprodukten zunimmt.
Der Länderabschnitt des Berichts enthält auch einzelne marktbeeinflussende Faktoren und Änderungen der Regulierung auf dem Inlandsmarkt, die sich auf die aktuellen und zukünftigen Markttrends auswirken. Datenpunkte wie Neuverkäufe, Ersatzverkäufe, demografische Daten des Landes, Regulierungsgesetze und Import-/Exportzölle sind einige der wichtigsten Anhaltspunkte, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Prognoseanalyse der Länderdaten werden auch die Präsenz und Verfügbarkeit europäischer Marken und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen der Vertriebskanäle berücksichtigt.
Wettbewerbsumfeld und Marktanteilsanalyse für Radiopharmazeutika in Europa
Die Wettbewerbslandschaft des europäischen Marktes für Radiopharmaka liefert Einzelheiten zu den Wettbewerbern. Die enthaltenen Einzelheiten umfassen Unternehmensübersicht, Unternehmensfinanzen, erzielten Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Produktionsstandorte und -anlagen, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktzulassungen, Produktbreite und -umfang, Anwendungsdominanz und Produkttyp-Lebenslinienkurve. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus des Unternehmens auf dem Markt.
Zu den wichtigsten Marktteilnehmern auf dem europäischen Markt für Radiopharmaka zählen unter anderem Cardinal Health, Advanced Accelerator Applications, A Novartis Company, Lantheus, CURIUM, Jubilant Radiopharma A Jubilant Pharmova Company, China Isotope & Radiation Corporation, Siemens Healthcare GmbH, Bracco, Eckert & Ziegler, SHINE Technologies, LLC, IBA Worldwide und Institute of Isotopes.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE RADIOPHARMACEUTICALS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 PIPELINE ANALYSIS
4.4 PATENT ANALYSIS
4.5 DRUG TREATMENT RATE BY MATURED MARKETS
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
4.7 PATIENT FLOW DIAGRAM
4.8 KEY PRICING STRATEGIES
4.9 KEY PATIENT ENROLLMENT STRATEGIES
5 LIST OF CYCLOTRONS
5.1 EUROPE
6 REGULATORY SCENARIO
6.1 EUROPE
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 THE GROWING DEMAND FOR RADIOPHARMACEUTICALS IN DIAGNOSTICS AND CLINICAL USE
7.1.2 THE INCREASING NEED FOR PHARMACEUTICAL PRODUCTS ACROSS VARIED THERAPEUTIC AREAS
7.1.3 THE INCREASING PREVALENCE OF CHRONIC DISEASES
7.2 RESTRAINTS
7.2.1 STRINGENT REGULATIONS FOR RADIOPHARMACEUTICALS
7.2.2 POTENTIAL RISKS ASSOCIATED WITH RADIOPHARMACEUTICALS
7.3 OPPORTUNITIES
7.3.1 THE RISING RESEARCH AND DEVELOPMENT EXPENDITURE OF RADIOPHARMACEUTICALS
7.3.2 THE GROWING INCIDENCES OF COMPLEX DISEASES IN GERIATRIC POPULATION
7.4 CHALLENGES
7.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS
7.4.2 LACK OF TECHNICAL EXPERTISE AND HIGH COST FOR TRAINING EXISTING WORKFORCE
8 EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE
8.1 OVERVIEW
8.2 DIAGNOSTIC RADIOPHARMACEUTICALS
8.2.1 PET RADIOPHARMACEUTICALS
8.2.1.1 F-18
8.2.1.2 RU-82
8.2.1.3 OTHER PET ISOTOPES RADIOPHARMACEUTICALS
8.2.2 SPECT RADIOPHARMACEUTICALS
8.2.2.1 TECHNETIUM-99M
8.2.2.2 GALLIUM-67
8.2.2.3 IODINE-123
8.2.2.4 THALLIUM-201
8.2.2.5 OTHER SPECT ISOTOPES
8.3 THERAPEUTIC RADIOPHARMACEUTICALS
8.3.1 BRACHYTHERAPY ISOTOPES
8.3.1.1 IODINE-125
8.3.1.2 PALLADIUM-103
8.3.1.3 CESIUM-131
8.3.1.4 IRIDIUM-192
8.3.1.5 OTHER BRACHYTHERAPY ISOTOPES
8.3.2 BETA EMITTERS
8.3.2.1 IODINE-131
8.3.2.2 LUTHETIUM-177
8.3.2.3 SAMARIUM-153
8.3.2.4 YTTRIUM-90
8.3.2.5 RHENIUM-186
8.3.2.6 OTHER BETA EMITTERS
8.3.3 ALPHA EMITTERS
8.3.3.1 RA-223
8.3.3.2 OTHERS
9 EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 DIAGNOSTIC
9.2.1 PET
9.2.1.1 ONCOLOGY
9.2.1.2 CARDIOLOGY
9.2.1.3 NEUROLOGY
9.2.1.4 OTHER PET APPLICATION
9.2.2 SPECT
9.2.2.1 CARDIOLOGY
9.2.2.2 BONE SCANS
9.2.2.3 THYROID APPLICATIONS
9.2.2.4 PULMONARY SCANS
9.2.2.5 OTHER SPECT APPLICATION
9.3 THERAPEUTIC
9.3.1 THYROID INDICATIONS
9.3.2 BONE METASTASIS
9.3.3 LYMPHOMA
9.3.4 ENDOCRINE TUMORS
9.3.5 OTHER INDICATIONS
10 EUROPE RADIOPHARMACEUTICALS MARKET, BY SOURCE
10.1 OVERVIEW
10.2 NUCLEAR REACTORS
10.3 CYCLOTRONS
11 EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 DIAGNOSTIC CENTERS
11.4 CANCER RESEARCH INSTITUTES
11.5 AMBULATORY SURGICAL CENTERS
11.6 OTHERS
12 EUROPE RADIOPHARMACEUTICAL MARKET
12.1 EUROPE
12.1.1 GERMANY
12.1.2 U.K.
12.1.3 FRANCE
12.1.4 ITALY
12.1.5 SPAIN
12.1.6 BELGIUM
12.1.7 POLAND
12.1.8 RUSSIA
12.1.9 NORWAY
12.1.10 TURKEY
12.1.11 AUSTRIA
12.1.12 IRELAND
12.1.13 HUNGARY
12.1.14 NETHERLANDS
12.1.15 SWITZERLAND
12.1.16 REST OF EUROPE
13 COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 CARDINAL HEALTH
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENT
15.2 ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 LANTHEUS
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.4 CURIUM
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENT
15.5 GENERAL ELECTRIC COMPANY
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 BRACCO
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 CHINA ISOTOPE & RADIATION CORPORATION
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 ECKERT & ZIEGLER
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 IBA WORLDWIDE
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 INSTITUTE OF ISOTOPES
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 JUBILANT RADIOPHARMA A JUBILANT PHARMOVA COMPANY
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 SHINE TECHNOLOGIES, LLC
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 SIEMENS HEALTHCARE GMBH
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 2 EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 3 EUROPE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 4 EUROPE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 5 EUROPE THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 6 EUROPE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 7 EUROPE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 8 EUROPE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 9 EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 11 EUROPE PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 13 EUROPE THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 15 EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 16 EUROPE RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 17 EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 18 EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 19 EUROPE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 20 EUROPE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 21 EUROPE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 22 EUROPE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 23 EUROPE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 24 EUROPE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 25 EUROPE THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 26 EUROPE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 27 EUROPE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 28 EUROPE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 29 EUROPE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 30 EUROPE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 31 EUROPE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 32 EUROPE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 33 EUROPE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 34 EUROPE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 35 EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 36 EUROPE DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 37 EUROPE PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 39 EUROPE THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 40 EUROPE RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 41 EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 42 GERMANY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 43 GERMANY DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 44 GERMANY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 45 GERMANY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 46 GERMANY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 47 GERMANY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 48 GERMANY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 49 GERMANY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 50 GERMANY THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 51 GERMANY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 52 GERMANY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 53 GERMANY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 54 GERMANY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 55 GERMANY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 56 GERMANY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 57 GERMANY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 58 GERMANY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 59 GERMANY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 60 GERMANY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 61 GERMANY DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 62 GERMANY PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 63 GERMANY SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 64 GERMANY THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 65 GERMANY RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 66 GERMANY RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 67 U.K. RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 68 U.K. DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 69 U.K. PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 70 U.K. PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 71 U.K. PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 72 U.K. SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 73 U.K. SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 74 U.K. SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 75 U.K. THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 76 U.K. BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 77 U.K. BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 78 U.K. BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 79 U.K. BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 80 U.K. BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 81 U.K. BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 82 U.K. ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 83 U.K. ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 84 U.K. ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 85 U.K. RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 86 U.K. DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 87 U.K. PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 88 U.K. SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 89 U.K. THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 90 U.K. RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 91 U.K. RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 92 FRANCE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 93 FRANCE DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 94 FRANCE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 95 FRANCE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 96 FRANCE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 97 FRANCE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 98 FRANCE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 99 FRANCE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 100 FRANCE THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 101 FRANCE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 102 FRANCE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 103 FRANCE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 104 FRANCE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 105 FRANCE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 106 FRANCE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 107 FRANCE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 108 FRANCE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 109 FRANCE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 110 FRANCE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 111 FRANCE DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 112 FRANCE PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 113 FRANCE SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 114 FRANCE THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 115 FRANCE RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 116 FRANCE RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 117 ITALY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 118 ITALY DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 119 ITALY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 120 ITALY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 121 ITALY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 122 ITALY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 123 ITALY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 124 ITALY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 125 ITALY THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 126 ITALY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 127 ITALY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 128 ITALY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 129 ITALY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 130 ITALY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 131 ITALY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 132 ITALY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 133 ITALY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 134 ITALY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 135 ITALY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 136 ITALY DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 137 ITALY PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 138 ITALY SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 139 ITALY THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 140 ITALY RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 141 ITALY RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 142 SPAIN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 143 SPAIN DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 144 SPAIN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 145 SPAIN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 146 SPAIN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 147 SPAIN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 148 SPAIN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 149 SPAIN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 150 SPAIN THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 151 SPAIN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 152 SPAIN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 153 SPAIN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 154 SPAIN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 155 SPAIN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 156 SPAIN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 157 SPAIN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 158 SPAIN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 159 SPAIN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 160 SPAIN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 161 SPAIN DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 162 SPAIN PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 163 SPAIN SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 164 SPAIN THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 165 SPAIN RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 166 SPAIN RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 167 BELGIUM RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 168 BELGIUM DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 169 BELGIUM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 170 BELGIUM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 171 BELGIUM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 172 BELGIUM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 173 BELGIUM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 174 BELGIUM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 175 BELGIUM THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 176 BELGIUM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 177 BELGIUM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 178 BELGIUM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 179 BELGIUM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 180 BELGIUM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 181 BELGIUM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 182 BELGIUM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 183 BELGIUM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 184 BELGIUM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 185 BELGIUM RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 186 BELGIUM DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 187 BELGIUM PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 188 BELGIUM SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 189 BELGIUM THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 190 BELGIUM RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 191 BELGIUM RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 192 POLAND RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 193 POLAND DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 194 POLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 195 POLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 196 POLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 197 POLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 198 POLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 199 POLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 200 POLAND THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 201 POLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 202 POLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 203 POLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 204 POLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 205 POLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 206 POLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 207 POLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 208 POLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 209 POLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 210 POLAND RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 211 POLAND DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 212 POLAND PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 213 POLAND SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 214 POLAND THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 215 POLAND RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 216 POLAND RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 217 RUSSIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 218 RUSSIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 219 RUSSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 220 RUSSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 221 RUSSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 222 RUSSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 223 RUSSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 224 RUSSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 225 RUSSIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 226 RUSSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 227 RUSSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 228 RUSSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 229 RUSSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 230 RUSSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 231 RUSSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 232 RUSSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 233 RUSSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 234 RUSSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 235 RUSSIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 236 RUSSIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 237 RUSSIA PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 238 RUSSIA SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 239 RUSSIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 240 RUSSIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 241 RUSSIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 242 NORWAY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 243 NORWAY DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 244 NORWAY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 245 NORWAY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 246 NORWAY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 247 NORWAY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 248 NORWAY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 249 NORWAY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 250 NORWAY THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 251 NORWAY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 252 NORWAY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 253 NORWAY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 254 NORWAY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 255 NORWAY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 256 NORWAY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 257 NORWAY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 258 NORWAY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 259 NORWAY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 260 NORWAY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 261 NORWAY DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 262 NORWAY PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 263 NORWAY SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 264 NORWAY THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 265 NORWAY RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 266 NORWAY RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 267 TURKEY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 268 TURKEY DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 269 TURKEY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 270 TURKEY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 271 TURKEY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 272 TURKEY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 273 TURKEY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 274 TURKEY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 275 TURKEY THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 276 TURKEY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 277 TURKEY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 278 TURKEY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 279 TURKEY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 280 TURKEY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 281 TURKEY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 282 TURKEY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 283 TURKEY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 284 TURKEY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 285 TURKEY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 286 TURKEY DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 287 TURKEY PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 288 TURKEY SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 289 TURKEY THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 290 TURKEY RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 291 TURKEY RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 292 AUSTRIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 293 AUSTRIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 294 AUSTRIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 295 AUSTRIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 296 AUSTRIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 297 AUSTRIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 298 AUSTRIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 299 AUSTRIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 300 AUSTRIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 301 AUSTRIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 302 AUSTRIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 303 AUSTRIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 304 AUSTRIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 305 AUSTRIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 306 AUSTRIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 307 AUSTRIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 308 AUSTRIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 309 AUSTRIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 310 AUSTRIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 311 AUSTRIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 312 AUSTRIA PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 313 AUSTRIA SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 314 AUSTRIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 315 AUSTRIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 316 AUSTRIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 317 IRELAND RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 318 IRELAND DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 319 IRELAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 320 IRELAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 321 IRELAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 322 IRELAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 323 IRELAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 324 IRELAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 325 IRELAND THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 326 IRELAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 327 IRELAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 328 IRELAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 329 IRELAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 330 IRELAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 331 IRELAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 332 IRELAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 333 IRELAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 334 IRELAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 335 IRELAND RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 336 IRELAND DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 337 IRELAND PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 338 IRELAND SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 339 IRELAND THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 340 IRELAND RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 341 IRELAND RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 342 HUNGARY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 343 HUNGARY DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 344 HUNGARY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 345 HUNGARY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 346 HUNGARY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 347 HUNGARY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 348 HUNGARY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 349 HUNGARY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 350 HUNGARY THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 351 HUNGARY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 352 HUNGARY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 353 HUNGARY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 354 HUNGARY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 355 HUNGARY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 356 HUNGARY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 357 HUNGARY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 358 HUNGARY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 359 HUNGARY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 360 HUNGARY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 361 HUNGARY DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 362 HUNGARY PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 363 HUNGARY SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 364 HUNGARY THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 365 HUNGARY RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 366 HUNGARY RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 367 NETHERLANDS RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 368 NETHERLANDS DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 369 NETHERLANDS PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 370 NETHERLANDS PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 371 NETHERLANDS PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 372 NETHERLANDS SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 373 NETHERLANDS SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 374 NETHERLANDS SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 375 NETHERLANDS THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 376 NETHERLANDS BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 377 NETHERLANDS BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 378 NETHERLANDS BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 379 NETHERLANDS BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 380 NETHERLANDS BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 381 NETHERLANDS BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 382 NETHERLANDS ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 383 NETHERLANDS ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 384 NETHERLANDS ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 385 NETHERLANDS RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 386 NETHERLANDS DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 387 NETHERLANDS PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 388 NETHERLANDS SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 389 NETHERLANDS THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 390 NETHERLANDS RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 391 NETHERLANDS RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 392 SWITZERLAND RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 393 SWITZERLAND DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 394 SWITZERLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 395 SWITZERLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 396 SWITZERLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 397 SWITZERLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 398 SWITZERLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 399 SWITZERLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 400 SWITZERLAND THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 401 SWITZERLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 402 SWITZERLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 403 SWITZERLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 404 SWITZERLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 405 SWITZERLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 406 SWITZERLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP IN MBQ)
TABLE 407 SWITZERLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 408 SWITZERLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 409 SWITZERLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 410 SWITZERLAND RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 411 SWITZERLAND DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 412 SWITZERLAND PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 413 SWITZERLAND SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 414 SWITZERLAND THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 415 SWITZERLAND RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 416 SWITZERLAND RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 417 REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
Abbildungsverzeichnis
FIGURE 1 EUROPE RADIOPHARMACEUTICALS: SEGMENTATION
FIGURE 2 EUROPE RADIOPHARMACEUTICALS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE RADIOPHARMACEUTICALS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE RADIOPHARMACEUTICALS MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE RADIOPHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE RADIOPHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE RADIOPHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE RADIOPHARMACEUTICALS MARKET: MARKET TYPE COVERAGE GRID
FIGURE 9 EUROPE RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 10 THE RISING PREVALENCE OF CHRONIC DISEASES IS EXPECTED TO DRIVE THE EUROPE RADIOPHARMACEUTICALS MARKET IN THE FORECAST PERIOD
FIGURE 11 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE RADIOPHARMACEUTICALS MARKET IN 2023 & 2030
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE RADIOPHARMACEUTICALS MARKET
FIGURE 13 EUROPE RADIOPHARMACEUTICALS MARKET: BY TYPE, 2022
FIGURE 14 EUROPE RADIOPHARMACEUTICALS MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 15 EUROPE RADIOPHARMACEUTICALS MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 16 EUROPE RADIOPHARMACEUTICALS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 17 EUROPE RADIOPHARMACEUTICALS MARKET: BY APPLICATION, 2022
FIGURE 18 EUROPE RADIOPHARMACEUTICALS MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 19 EUROPE RADIOPHARMACEUTICALS MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 20 EUROPE RADIOPHARMACEUTICALS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 21 EUROPE RADIOPHARMACEUTICALS MARKET: BY SOURCE, 2022
FIGURE 22 EUROPE RADIOPHARMACEUTICALS MARKET: BY SOURCE, 2023-2030 (USD MILLION)
FIGURE 23 EUROPE RADIOPHARMACEUTICALS MARKET: BY SOURCE, CAGR (2023-2030)
FIGURE 24 EUROPE RADIOPHARMACEUTICALS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 25 EUROPE RADIOPHARMACEUTICALS MARKET: BY END USER, 2022
FIGURE 26 EUROPE RADIOPHARMACEUTICALS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 27 EUROPE RADIOPHARMACEUTICALS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 28 EUROPE RADIOPHARMACEUTICALS MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 EUROPE RADIOPHARMACEUTICALS MARKET: SNAPSHOT (2022)
FIGURE 30 EUROPE RADIOPHARMACEUTICALS MARKET: BY COUNTRY (2022)
FIGURE 31 EUROPE RADIOPHARMACEUTICALS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 32 EUROPE RADIOPHARMACEUTICALS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 33 EUROPE RADIOPHARMACEUTICALS MARKET: BY TYPE (2023-2030)
FIGURE 34 EUROPE RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2022 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
